Equities Analysts Issue Forecasts for NTLA Q2 Earnings

Key Points

• Brookline Capital Markets lowered Intellia’s Q2 2026 EPS forecast to a loss of $0.80 per share from $0.75, while projecting continued losses through 2026 before a possible return to profitability in 2027.
• Intellia reported a Q2 loss of $0.80 per share, in line with consensus, but revenue of $7.66 million fell well short of the $12.98 million analyst estimate and declined 46.4% year over year.
• Analyst sentiment remains mixed: the stock carries a consensus Hold rating with a $20.85 price target, alongside recent Buy, Neutral and Strong Sell calls. Shares opened at $11.94, with a market capitalization of approximately $1.67 billion.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Brookline Capital Markets lowered their Q2 2026 earnings estimates for Intellia Therapeutics in a report issued on Thursday, August 6th. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn ($0.80) per share for the quarter, down from their previous estimate of ($0.75). The consensus estimate for Intellia Therapeutics' current full-year earnings is ($3.18) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics' Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($2.84) EPS, FY2027 earnings at $0.97 EPS, FY2028 earnings at $5.53 EPS, FY2029 earnings at $14.89 EPS and FY2030 earnings at $25.07 EPS.

Other equities research analysts have also issued reports about the stock. Robert W. Baird lifted their price target on shares of Intellia Therapeutics from $7.00 to $13.00 and gave the stock a "neutral" rating in a research note on Monday, April 27th. Chardan Capital raised their price objective on Intellia Therapeutics from $27.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, April 27th. Wall Street Zen cut Intellia Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday. Canaccord Genuity Group reissued a "buy" rating and issued a $49.00 target price on shares of Intellia Therapeutics in a report on Tuesday, June 16th. Finally, Morgan Stanley upped their target price on Intellia Therapeutics from $11.00 to $15.00 and gave the company an "equal weight" rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have issued a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $20.85.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $11.94 on Monday. The company has a market capitalization of $1.67 billion, a PE ratio of -3.55 and a beta of 1.81. Intellia Therapeutics has a twelve month low of $7.95 and a twelve month high of $28.25. The firm has a 50 day simple moving average of $13.65 and a 200-day simple moving average of $13.48.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, hitting the consensus estimate of ($0.80). The firm had revenue of $7.66 million during the quarter, compared to analysts' expectations of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The firm's revenue was down 46.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.98) earnings per share.

Insiders Place Their Bets

In related news, EVP Edward J. Dulac III sold 4,677 shares of the firm's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares of the company's stock, valued at $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Michael P. Dube sold 2,641 shares of the business's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the transaction, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This trade represents a 3.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.50% of the company's stock.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently added to or reduced their stakes in NTLA. Wealthfront Advisers LLC acquired a new position in shares of Intellia Therapeutics in the second quarter valued at approximately $308,000. Grandfield & Dodd LLC purchased a new position in Intellia Therapeutics in the 2nd quarter valued at $841,000. BlackRock Inc. acquired a new position in Intellia Therapeutics in the 2nd quarter valued at $260,721,000. Deutsche Bank AG purchased a new position in Intellia Therapeutics during the 2nd quarter worth $3,563,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Intellia Therapeutics in the 2nd quarter worth $363,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Evercore ISI upgraded Intellia Therapeutics, citing its “nex-z hypothesis.” The upgrade suggests the firm sees potential for the program to create meaningful long-term value and improve the company’s outlook. Intellia upgraded at Evercore ISI on nex-z hypothesis
• Positive Sentiment: Brookline Capital Markets modestly improved its fourth-quarter 2026 EPS forecast to a loss of $0.41 from a loss of $0.47. Its longer-term model still projects a return to profitability beginning in 2027, which may support the investment case if clinical development succeeds. Brookline Capital Markets estimates
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating that it does not currently see a strong enough catalyst to recommend buying or selling the shares. Bank of America Securities remains a Hold on Intellia Therapeutics
• Neutral Sentiment: Recent analysis highlighted narrowing losses but continued heavy research-and-development spending. Intellia’s latest quarterly revenue also trailed estimates, underscoring that the company remains dependent on clinical progress rather than current operating revenue. Will Intellia’s narrowing losses and heavy R&D spend shift its risk reward narrative?
• Negative Sentiment: Brookline reduced its EPS forecasts for the second and third quarters of 2026 and lowered the full-year estimate to a $2.84 loss from a $2.76 loss. More significantly, it sharply cut projected earnings for 2027–2030, signaling substantially lower expectations for Intellia’s eventual commercial opportunity.
• Negative Sentiment: Wall Street Zen downgraded NTLA to Strong Sell. Together with the lower long-term estimates and BofA’s Hold rating, the call reflects substantial uncertainty around clinical execution, cash usage and the timing of profitability. Intellia lowered to Strong Sell rating

About Intellia Therapeutics

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source